Heart failure & cardiomyopathies
Economic Aspects of Long-Term Left Ventricular Assist Device Treatment for Chronic Heart Failure
Authors' conclusion
LVAD implantation in patients with end-stage heart failure leads to improved survival but a significant increase in treatment costs.
Study context
- Population
- Patients with end-stage HF after left ventricular assist device (LVAD) implantation75.5% male
- Participants
- 163 patients
- Outcome
- Long-term costs of LVAD therapy (revenue per patient)
Methodological detailsMean age at LVAD implantation 52 ± 14 years
- Mean age at LVAD implantation 52 ± 14 years
Main finding
As reported in the abstract
Average revenue per patient
Implant stay
$193 192.35 ± $111 801.29
Inpatient readmissions
$52 068.96 ± $116 630.00
Outpatient care
$53 195.94 ± $62 363.53
Observational data: associations, not effects.
Further findings
Mean survival
- Mean survival
- 1458 ± 127 days
Treatment time during follow-up
- Total inpatient treatment time per patient
- 70 ± 87 days
- Average duration of outpatient treatment, % of total duration of support
- 55.1%
Original publication
Economic Aspects of Long-Term Left Ventricular Assist Device Treatment for Chronic Heart Failure. ESC Heart Fail. Published 20 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →